Heavily-anticipated results from COMPASS Pathways’ Phase 2b study of psilocybin-assisted therapy for treatment-resistant depression (TRD) are expected to be announced in the coming weeks. In this special issue we explore the significance of these forthcoming results and aim to provide a primer on their interpretation. Company Indication Phase I Phase II Phase III MAPS is currently conducting Phase…


Previous articlePsychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin
Next articlePT271 – Jeremy Narby, Ph.D. – Anthropology, Ayahuasca, and Plant Teachers